Amador Bioscience is a Translational & Clinical CRO providing global-standard quantitative clinical pharmacology, GLP/GCLP bioanalysis, clinical research, and regulatory filing services to biopharmaceutical companies in China, USA and EU. Amador is committed to facilitating innovative drug development from discovery to clinical development and global regulatory fillings. Since its inception in 2018, Amador Bioscience has actively supported 80+ clinical projects, multiple IND and 6 CTD filings in USA and China. Our clients range from cutting-edge biotech startups to industry-leading multinationals.